Table 1. Summary of papers found by literature search that meet the inclusion criteria.
Study author | Type of study | Total number of patients | Surgery | Follow-up time | Comparison | Aspirin dose | Outcome measure |
---|---|---|---|---|---|---|---|
Raphael et al, 2014 15 | Retrospective study | 28,923 | Total joint arthroplasty | 90 d | Aspirin vs. variable dose warfarin | 325 mg BD | Symptomatic VTE, complications, mortality. |
Jiang et al, 2014 16 | RCT | 120 | Total knee arthroplasty | Unknown | Aspirin vs. LMWH/ rivaroxaban | Unknown | Incidence of VTE |
Zou et al, 2014 17 | RCT | 324 | Total knee arthroplasty | Unknown | Aspirin vs. LMWH vs. rivaroxaban | 100 mg/day | Incidence of DVT, complications |
Na et al, 2015 18 | Retrospective study | 328 | Total knee arthroplasty | 3 mo | Aspirin vs. LMWH and aspirin | 100 mg/d | Incidence of DVT or PE, complications |
Asopa et al, 2015 19 | Retrospective study | 9,035 | Hip and knee arthroplasty | 6 wk | n/a | 300 mg/d only given on discharge | Incidence of symptomatic VTE |
Pow and Vale, 2015 20 | Retrospective study | 402 | Total hip and knee arthroplasty | Unknown | Aspirin vs. anticoagulants in hospital and discharge | Unknown | VTE prophylaxis prescribing, incidence of VTE |
Ogonda et al, 2016 21 | Retrospective study | 11,459 | Total hip, total knee, and unicompartmental knee arthroplasty | 3 mo | Aspirin vs. National Joint Registry rates | 150 mg/d | Incidence of DVT and PE, mortality |
Yhim et al, 2017 22 | Retrospective study | 306,912 | Total hip and knee arthroplasty | 3 mo | Aspirin vs. anticoagulants and no thromboprophylaxis | Unknown | Incidence of VTE, prescription rates |
Abbreviations: BD, twice a day; DVT, deep vein thrombosis; LMWH, low molecular weight heparin; PE, pulmonary embolism; RCT, randomized control trial; VTE, venous thromboembolism.